Summary: Immobilization-related hypercalcaemia is an uncommon but important condition being associated not infrequently with both urolithiasis and osteoporosis. In this study 5 
Introduction
Immobilization-related hypercalcaemia was first described by Albright in 1941. ' Although it is an uncommon condition hypercalciuria and negative calcium balance is common with resulting osteoporosis.2 Generally immobilization-related hypercalcaemia is associated with conditions where bone turnover is high such as in children, adolescents3 or in patients with Paget's disease of bone.4 In the patients described in this study these conditions were not present but rather all cases were associated with sepsis which may be a hitherto unrecognized aetiological factor in this syndrome. We and others have found pamidronate (aminohydroxypropylidene bisphosphonate) to be of value in the treatment of the accelerated bone resorption associated with hypercalcaemia of malignancys and Paget's disease of bone.6 Since increased bone resorption is also the major factor in immobilization-related hypercalcaemia7 '8 we looked at the effects of pamidronate on 5 patients with this syndrome.
Patients and methods
The details of patients studied are shown in Table I Previous work using radiolabelled calcium7 and the incorporation of tetracycline into bone8 has suggested the mechanism of the hypercalciuria and osteoporosis to be due to increased bone resorption and decreased bone formation. The high urinary OH-Prol/creatinine and calcium/creatinine ratios would be consistent with this hypothesis. However, the data from the bone biopsies suggest that while bone resorption tends to be increased, bone formation rates are normal.
The patients in this study were 
